Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGLE-102 for Recessive Dystrophic Epidermolysis Bullosa Wounds
NCT04173650Phase 2Recruiting
- Sponsor
- Aegle Therapeutics
- Start
- Aug 2024
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of AGLE-102 in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Aegle Therapeutics. Started Aug 2024; status: recruiting.
02
Drugs
AGLE-102
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT04173650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173650.